Clinical Trials

MyeloidOther hematologic neoplasmSarcoma

100 enrolled

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

508 enrolled

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT06928662 2026-05-15

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Phase 1/2 Recruiting

36 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07561892 2026-05-01

AML

Phase 4 Recruiting

100 enrolled

Leukemia, Myeloid, Acute

NCT06578247 2026-04-30

QuANTUM-WILD

700 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT05586074 2026-04-28

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

324 enrolled

Leukemia, Myeloid, Acute

NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

171 enrolled

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07514832 2026-04-07

VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial

48 enrolled

Leukemia, Myeloid, Acute

NCT07223814 2026-04-06

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

875 enrolled

Leukemia, Myeloid, Acute

NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Classical hematologyOther hematologic neoplasm

270 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

NCT05260528 2026-03-27

ALFA2101

248 enrolled

Leukemia, Myeloid, Acute

NCT03214562 2026-03-05

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Recruiting

116 enrolled

Leukemia, Myeloid, Acute

NCT04375631 2026-03-05

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Phase 1 Recruiting

120 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07132684 2026-03-02

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

240 enrolled

Leukemia, Myeloid, Acute

NCT07046078 2026-01-30

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

20 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07228273 2026-01-22

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

102 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04047641 2025-12-17

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1/2 Recruiting

80 enrolled

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT07232134 2025-11-20

AML-DS-2025

100 enrolled

Down Syndrome, Leukemia, Myeloid, Acute

NCT06451861 2025-11-17

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

240 enrolled

Phase EARLY_PHASE1 Recruiting

Leukemia, Myeloid, Acute

NCT07059975 2025-11-04

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

36 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Phase NA Recruiting

120 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06221683 2024-08-22

GMCAII

500 enrolled

Leukemia, Myeloid, Acute

NCT06316960 2024-08-22

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

50 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT02416388 2024-08-07

BIG-1

Phase 2/3 Recruiting

3,100 enrolled

Leukemia, Myeloid, Acute

NCT06492408 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06492421 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06483347 2024-07-03

Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

Thoracic

Lung Neoplasms

NCT06482801 2024-07-01

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06232694 2024-01-31

Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML

Phase NA Recruiting

54 enrolled